LUC00313I2 - - Google Patents
Info
- Publication number
- LUC00313I2 LUC00313I2 LU00313C LUC00313C LUC00313I2 LU C00313 I2 LUC00313 I2 LU C00313I2 LU 00313 C LU00313 C LU 00313C LU C00313 C LUC00313 C LU C00313C LU C00313 I2 LUC00313 I2 LU C00313I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723840P | 2012-11-08 | 2012-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LUC00313I2 true LUC00313I2 (https=) | 2026-02-02 |
Family
ID=49876960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00313C LUC00313I2 (https=) | 2012-11-08 | 2023-08-07 |
Country Status (40)
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2648226T3 (es) | 2012-11-08 | 2017-12-29 | Bristol-Myers Squibb Company | Compuestos de pirimidina sustituidos con alquilamida útiles en la modulación de IL-12, IL-23 y/o IFN |
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| US9834548B2 (en) | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
| CR20180285A (es) * | 2015-11-26 | 2018-07-16 | Novartis Ag | Derivados novedosos de diamino piridina |
| US10323036B2 (en) | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| AR110351A1 (es) * | 2016-12-13 | 2019-03-20 | Bristol Myers Squibb Co | COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| TW202515876A (zh) | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| JP7113023B2 (ja) * | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| EA202091269A1 (ru) * | 2017-11-21 | 2020-08-07 | Бристол-Маерс Сквибб Компани | Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| CN111936486B (zh) * | 2018-03-22 | 2023-09-22 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
| KR102848769B1 (ko) * | 2018-05-31 | 2025-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태 |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| CA3120866A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CN113348021B (zh) | 2019-01-23 | 2025-07-11 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| CN115448910B (zh) * | 2019-01-28 | 2024-04-19 | 江苏豪森药业集团有限公司 | 一种哒嗪类衍生物抑制剂、其制备方法和应用 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| SG11202108162SA (en) * | 2019-01-30 | 2021-08-30 | Bristol Myers Squibb Co | Amide-disubstituted pyridine or pyridazine compounds |
| SG11202112043PA (en) | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| US11357775B2 (en) | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| US12570637B2 (en) | 2019-06-12 | 2026-03-10 | Bristol-Myers Squibb Company | Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide |
| WO2021011513A1 (en) | 2019-07-16 | 2021-01-21 | Bristol-Myers Squibb Company | Prodrugs in the modulation of interleukin |
| US12428395B2 (en) | 2019-08-01 | 2025-09-30 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| MX2022002877A (es) | 2019-09-13 | 2022-08-08 | Nimbus Saturn Inc | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. |
| JP7812785B2 (ja) | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| CN114787152A (zh) * | 2019-12-27 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165晶型及其制备方法和用途 |
| WO2021143430A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型及其制备方法和用途 |
| CN114787154A (zh) * | 2020-01-19 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| WO2021170046A1 (en) * | 2020-02-26 | 2021-09-02 | Beigene, Ltd. | Tyk-2 inhibitor |
| SMT202400185T1 (it) * | 2020-03-11 | 2024-07-09 | Beijing Innocare Pharma Tech Co Ltd | Composti eterociclici per inibire attività di tyk2 |
| WO2021204626A1 (en) * | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| KR20230004771A (ko) * | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
| CN113563309B (zh) * | 2020-04-28 | 2024-12-13 | 浙江海正药业股份有限公司 | 吡啶类衍生物及其制备方法和用途 |
| CN113735837B (zh) * | 2020-05-28 | 2023-09-01 | 江苏先声药业有限公司 | 哒嗪类化合物及其用途 |
| CN113735836B (zh) * | 2020-05-28 | 2023-05-30 | 江苏先声药业有限公司 | 哒嗪类化合物及其应用 |
| CN113773262B (zh) * | 2020-06-09 | 2024-08-09 | 江苏先声药业有限公司 | 哒嗪类化合物 |
| KR20230042278A (ko) | 2020-06-22 | 2023-03-28 | 베이진 엘티디 | Tyk-2 저해제 |
| CN115667246B (zh) * | 2020-07-24 | 2024-08-23 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 |
| CN113968846A (zh) * | 2020-07-24 | 2022-01-25 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物的盐、晶型及其制备方法和应用 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN114057651B (zh) * | 2020-07-31 | 2025-05-27 | 正大天晴药业集团股份有限公司 | 含酰胺基的tyk2抑制剂化合物 |
| WO2022021684A1 (zh) * | 2020-07-31 | 2022-02-03 | 苏州科睿思制药有限公司 | 一种bms-986165盐酸盐晶型csv及其制备方法和用途 |
| IL301389A (en) | 2020-09-18 | 2023-05-01 | Bristol Myers Squibb Co | Dosage forms for tyk2 inhibitors comprising swellable cores |
| WO2022083649A1 (zh) * | 2020-10-20 | 2022-04-28 | 杭州领业医药科技有限公司 | 哒嗪衍生物的晶型 |
| US12331046B2 (en) | 2020-10-23 | 2025-06-17 | Nimbus Clotho, Inc. | CTPS1 inhibitors and uses thereof |
| WO2022100710A1 (en) * | 2020-11-12 | 2022-05-19 | Cullgen (Shanghai) , Inc. | Tyrosine kinase 2 (tyk2) degradation compounds and methods of use |
| TW202227430A (zh) * | 2020-11-17 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
| CN116547276A (zh) * | 2020-12-08 | 2023-08-04 | 正大天晴药业集团股份有限公司 | 含酰胺基和杂环烷基的tyk2抑制剂化合物 |
| US12492184B2 (en) | 2020-12-22 | 2025-12-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| CN114805438A (zh) * | 2021-01-18 | 2022-07-29 | 正大天晴药业集团股份有限公司 | 含磷酰基的tyk2抑制剂化合物 |
| KR20230137962A (ko) * | 2021-01-29 | 2023-10-05 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태 |
| MX2023009060A (es) | 2021-02-02 | 2023-09-29 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| CN114907326B (zh) * | 2021-02-06 | 2025-02-18 | 正大天晴药业集团股份有限公司 | 含酰胺基和联环的tyk2抑制剂化合物 |
| TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 |
| EP4291235A4 (en) | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| CA3213816A1 (en) * | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN117377667A (zh) * | 2021-03-29 | 2024-01-09 | 百时美施贵宝公司 | 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型 |
| WO2022206705A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江文达医药科技有限公司 | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 |
| CN115197196B (zh) * | 2021-04-06 | 2024-06-18 | 扬子江药业集团有限公司 | Tyk2抑制剂及其用途 |
| US12325697B2 (en) | 2021-04-09 | 2025-06-10 | Nimbus Clio, Inc. | CBL-B modulators and uses thereof |
| JP7740849B2 (ja) * | 2021-05-04 | 2025-09-17 | シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド | 含窒素複素環ピリジン化合物 |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| KR20240008337A (ko) | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2022253335A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 含磺酰基的芳基类化合物及其应用 |
| CN115466289A (zh) * | 2021-06-11 | 2022-12-13 | 爱科诺生物医药(香港)有限公司 | 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用 |
| CA3223641A1 (en) * | 2021-06-22 | 2022-12-29 | Wenyuan Qian | Sulfoximine compound and use thereof |
| JP2024535865A (ja) * | 2021-07-15 | 2024-10-02 | メッドシャイン ディスカバリー インコーポレイテッド | 硫黄／リン含有アリール系化合物及びその使用 |
| EP4387968B1 (en) | 2021-08-20 | 2025-11-12 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| WO2023027948A1 (en) * | 2021-08-21 | 2023-03-02 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| EP4404930A1 (en) | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| US20240390369A1 (en) | 2021-09-30 | 2024-11-28 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| JP2024539703A (ja) * | 2021-10-28 | 2024-10-29 | ブリストル－マイヤーズ スクイブ カンパニー | デュークラバシチニブの局所製剤 |
| EP4441043A1 (en) | 2021-12-01 | 2024-10-09 | Teva Czech Industries s.r.o | Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| AU2022412835A1 (en) | 2021-12-16 | 2024-06-20 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| CN116283928A (zh) * | 2021-12-20 | 2023-06-23 | 艾立康药业股份有限公司 | 一种哒嗪类化合物、其制备方法和应用 |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| CN116693449A (zh) * | 2022-03-04 | 2023-09-05 | 上海致根医药科技有限公司 | 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用 |
| CN119233971A (zh) * | 2022-05-31 | 2024-12-31 | 上海华汇拓医药科技有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN117447411B (zh) * | 2022-07-18 | 2025-12-23 | 苏州鹏旭医药科技有限公司 | 一种杂环药物中间体的合成方法 |
| WO2024020221A1 (en) | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| IL318577A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES |
| US20260028330A1 (en) | 2022-08-02 | 2026-01-29 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| KR20250056924A (ko) | 2022-08-02 | 2025-04-28 | 리미널 바이오사이언시스 리미티드 | 치환된 피리돈 gpr84 길항제 및 이의 용도 |
| CN120152968A (zh) | 2022-11-08 | 2025-06-13 | 百时美施贵宝公司 | 取代的杂环化合物 |
| AR131375A1 (es) | 2022-12-16 | 2025-03-12 | Alembic Pharmaceuticals Ltd | Ligandos de pseudoquinasa tyk2 y sus usos |
| CN116284040B (zh) * | 2023-01-05 | 2024-05-28 | 华润医药研究院（深圳）有限公司 | 含氮杂环类化合物及其医药用途 |
| CN120693328A (zh) * | 2023-02-07 | 2025-09-23 | 浙江华海药业股份有限公司 | 一种哒嗪类化合物、其制备方法和用途 |
| CN118724752B (zh) * | 2023-03-29 | 2025-11-28 | 重庆博腾制药科技股份有限公司 | 一种酪氨酸激酶抑制剂中间体、制备方法及其应用 |
| CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
| EP4713315A1 (en) * | 2023-05-15 | 2026-03-25 | Alivus Life Sciences Limited | Process for the preparation of deucravacitinib, and crystalline forms thereof |
| CN119080742A (zh) * | 2023-06-05 | 2024-12-06 | 甘莱制药有限公司 | 脂质合成的杂环调节剂的工业化制备 |
| WO2024257023A1 (en) | 2023-06-14 | 2024-12-19 | Alembic Pharmaceuticals Limited | Tyk2 pseudokinase ligands and uses thereof |
| AU2024344754A1 (en) | 2023-09-21 | 2026-04-02 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| CN117447353B (zh) * | 2023-09-21 | 2025-12-30 | 爱斯特（成都）生物制药股份有限公司 | 一种氘可来昔替尼中间体的制备方法 |
| EP4538259A1 (en) | 2023-10-09 | 2025-04-16 | Farmhispania Group, S.L. | Processes for the preparation of deucravacitinib |
| WO2025131031A1 (zh) * | 2023-12-22 | 2025-06-26 | 上海奥博生物医药股份有限公司 | 一种TyK2抑制剂及其中间体的制备方法 |
| WO2025173029A1 (en) * | 2024-02-14 | 2025-08-21 | Natco Pharma Limited | An improved process for the preparation of deucravacitinib |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
| CN119059972B (zh) * | 2024-08-12 | 2025-10-28 | 武汉九州钰民医药科技有限公司 | 一种btk抑制剂吡托布鲁替尼的合成方法 |
| ES3059443A1 (es) | 2024-09-17 | 2026-03-20 | Moehs Iberica Sl | Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib |
| CN120607493B (zh) * | 2025-06-04 | 2026-04-24 | 江西科技师范大学 | 一种含嘧啶结构的酰胺类化合物及其在制备tyk2 jh2激酶抑制剂中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE288420T1 (de) | 1999-06-09 | 2005-02-15 | Yamanouchi Pharma Co Ltd | Neuartige heterocyclische carboxamid-derivate |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| WO2000076980A1 (en) * | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| US7314623B2 (en) | 2002-07-15 | 2008-01-01 | Wyeth | Methods and compositions for modulating T helper (Th) cell development and function |
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US20130096104A1 (en) * | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| TW201217387A (en) | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
| BR112013011520A2 (pt) | 2010-11-19 | 2019-09-24 | Hoffmann La Roche | pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2 |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| CN104159891B (zh) * | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
| UY34807A (es) * | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| US9040530B2 (en) * | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| WO2014060371A1 (en) | 2012-10-19 | 2014-04-24 | F. Hoffmann-La Roche Ag | Inhibitors of syk |
| LT3495358T (lt) * | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| KR102233252B1 (ko) | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| ES2648226T3 (es) | 2012-11-08 | 2017-12-29 | Bristol-Myers Squibb Company | Compuestos de pirimidina sustituidos con alquilamida útiles en la modulación de IL-12, IL-23 y/o IFN |
| TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| JP7113023B2 (ja) | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
-
2013
- 2013-11-07 LT LTEP18197550.9T patent/LT3495358T/lt unknown
- 2013-11-07 HR HRP20220766TT patent/HRP20220766T1/hr unknown
- 2013-11-07 PT PT181975509T patent/PT3495358T/pt unknown
- 2013-11-07 SI SI201331986T patent/SI3495358T1/sl unknown
- 2013-11-07 MY MYPI2022004735A patent/MY198262A/en unknown
- 2013-11-07 PT PT13811640T patent/PT2922846T/pt unknown
- 2013-11-07 SG SG10201706985UA patent/SG10201706985UA/en unknown
- 2013-11-07 PE PE2015000607A patent/PE20150944A1/es active IP Right Grant
- 2013-11-07 LT LTEP13811640.5T patent/LT2922846T/lt unknown
- 2013-11-07 NZ NZ708859A patent/NZ708859A/en unknown
- 2013-11-07 BR BR112015010102-0A patent/BR112015010102B1/pt active IP Right Grant
- 2013-11-07 SG SG10201706897TA patent/SG10201706897TA/en unknown
- 2013-11-07 US US14/441,183 patent/US9505748B2/en not_active Ceased
- 2013-11-07 ES ES13811640T patent/ES2702148T3/es active Active
- 2013-11-07 CA CA2890981A patent/CA2890981C/en active Active
- 2013-11-07 AR ARP130104091A patent/AR094452A1/es active IP Right Grant
- 2013-11-07 RS RS20181428A patent/RS58187B1/sr unknown
- 2013-11-07 SM SM20190001T patent/SMT201900001T1/it unknown
- 2013-11-07 HU HUE18197550A patent/HUE059409T2/hu unknown
- 2013-11-07 PL PL18197550T patent/PL3495358T3/pl unknown
- 2013-11-07 UY UY0001035126A patent/UY35126A/es unknown
- 2013-11-07 SM SM20220258T patent/SMT202200258T1/it unknown
- 2013-11-07 AU AU2013341186A patent/AU2013341186B2/en active Active
- 2013-11-07 MY MYPI2015701475A patent/MY175448A/en unknown
- 2013-11-07 TW TW102140572A patent/TWI605041B/zh active
- 2013-11-07 HU HUE13811640A patent/HUE041750T2/hu unknown
- 2013-11-07 US US16/201,653 patent/USRE47929E1/en active Active
- 2013-11-07 ES ES18197550T patent/ES2914793T3/es active Active
- 2013-11-07 JP JP2015541883A patent/JP6407159B2/ja active Active
- 2013-11-07 WO PCT/US2013/068846 patent/WO2014074661A1/en not_active Ceased
- 2013-11-07 RS RS20220589A patent/RS63328B1/sr unknown
- 2013-11-07 SI SI201331219T patent/SI2922846T1/sl unknown
- 2013-11-07 CN CN201380069692.9A patent/CN104884454B/zh active Active
- 2013-11-07 EA EA201590917A patent/EA028814B1/ru not_active IP Right Cessation
- 2013-11-07 EP EP18197550.9A patent/EP3495358B8/en active Active
- 2013-11-07 MY MYPI2020005025A patent/MY194668A/en unknown
- 2013-11-07 DK DK18197550.9T patent/DK3495358T3/da active
- 2013-11-07 MX MX2015005731A patent/MX2015005731A/es active IP Right Grant
- 2013-11-07 PL PL13811640T patent/PL2922846T3/pl unknown
- 2013-11-07 KR KR1020157014694A patent/KR102195194B1/ko active Active
- 2013-11-07 HR HRP20181937TT patent/HRP20181937T1/hr unknown
- 2013-11-07 EP EP13811640.5A patent/EP2922846B1/en active Active
- 2013-11-07 MA MA38072A patent/MA38072A1/fr unknown
- 2013-11-07 DK DK13811640.5T patent/DK2922846T3/en active
- 2013-11-07 SG SG11201503399XA patent/SG11201503399XA/en unknown
- 2013-11-07 TR TR2018/20824T patent/TR201820824T4/tr unknown
- 2013-11-07 EP EP22165094.8A patent/EP4071144A1/en active Pending
-
2015
- 2015-05-04 IL IL238610A patent/IL238610A0/en active IP Right Grant
- 2015-05-06 MX MX2020003156A patent/MX2020003156A/es unknown
- 2015-05-06 PH PH12015501004A patent/PH12015501004A1/en unknown
- 2015-05-07 CL CL2015001231A patent/CL2015001231A1/es unknown
- 2015-06-05 ZA ZA2015/04052A patent/ZA201504052B/en unknown
-
2016
- 2016-10-10 US US15/289,437 patent/US10000480B2/en active Active
-
2017
- 2017-02-17 AU AU2017201076A patent/AU2017201076B2/en active Active
-
2018
- 2018-05-15 US US15/979,770 patent/US10526321B2/en active Active
- 2018-05-16 JP JP2018094837A patent/JP6585231B2/ja active Active
- 2018-11-19 AU AU2018267545A patent/AU2018267545B2/en active Active
- 2018-12-14 CY CY20181101343T patent/CY1121188T1/el unknown
-
2019
- 2019-09-04 JP JP2019161215A patent/JP2020002157A/ja active Pending
- 2019-11-18 US US16/687,279 patent/US11021475B2/en active Active
-
2020
- 2020-06-15 AU AU2020203967A patent/AU2020203967B2/en active Active
-
2021
- 2021-04-29 US US17/244,938 patent/US20220356180A1/en not_active Abandoned
-
2022
- 2022-06-02 CY CY20221100391T patent/CY1125220T1/el unknown
-
2023
- 2023-07-24 NL NL301238C patent/NL301238I2/nl unknown
- 2023-07-27 CY CY2023017C patent/CY2023017I2/el unknown
- 2023-08-07 LU LU00313C patent/LUC00313I2/fr unknown
- 2023-08-10 HU HUS2300025C patent/HUS2300025I1/hu unknown
- 2023-08-14 FR FR23C1030C patent/FR23C1030I2/fr active Active
- 2023-08-23 LT LTPA2023523C patent/LTC2922846I2/lt unknown
- 2023-08-25 NO NO2023032C patent/NO2023032I1/no unknown
- 2023-08-28 FI FIC20230028C patent/FIC20230028I1/fi unknown
-
2024
- 2024-09-10 US US18/830,387 patent/US20250243193A1/en active Pending